WallStSmart

DoorDash, Inc. Class A Common Stock (DASH)vsMerck & Company Inc (MRK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 374% more annual revenue ($65.01B vs $13.72B). MRK leads profitability with a 28.1% profit margin vs 6.8%. DASH appears more attractively valued with a PEG of 1.58. MRK earns a higher WallStSmart Score of 59/100 (C).

DASH

Buy

59

out of 100

Grade: C

Growth: 10.0Profit: 5.5Value: 4.7Quality: 7.5
Piotroski: 5/9Altman Z: 1.94

MRK

Buy

59

out of 100

Grade: C

Growth: 4.0Profit: 9.5Value: 4.7Quality: 4.8
Piotroski: 3/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

DASHSignificantly Overvalued (-75.2%)

Margin of Safety

-75.2%

Fair Value

$100.15

Current Price

$152.92

$52.77 premium

UndervaluedFair: $100.15Overvalued
MRKSignificantly Overvalued (-141.2%)

Margin of Safety

-141.2%

Fair Value

$49.50

Current Price

$119.37

$69.87 premium

UndervaluedFair: $49.50Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

DASH3 strengths · Avg: 9.0/10
Revenue GrowthGrowth
37.7%10/10

Revenue surging 37.7% year-over-year

Market CapQuality
$67.22B9/10

Large-cap with strong market position

EPS GrowthGrowth
47.7%8/10

Earnings expanding 47.7% YoY

MRK6 strengths · Avg: 9.2/10
Market CapQuality
$287.71B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
36.9%10/10

Every $100 of equity generates 37 in profit

Operating MarginProfitability
32.8%10/10

Strong operational efficiency at 32.8%

Profit MarginProfitability
28.1%9/10

Keeps 28 of every $100 in revenue as profit

P/E RatioValuation
16.0x8/10

Attractively priced relative to earnings

Free Cash FlowQuality
$1.82B8/10

Generating 1.8B in free cash flow

Areas to Watch

DASH4 concerns · Avg: 3.3/10
PEG RatioValuation
1.584/10

Expensive relative to growth rate

Altman Z-ScoreHealth
1.944/10

Grey zone — moderate risk

Profit MarginProfitability
6.8%3/10

6.8% margin — thin

P/E RatioValuation
72.3x2/10

Premium valuation, high expectations priced in

MRK3 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
3.492/10

Expensive relative to growth rate

EPS GrowthGrowth
-19.3%2/10

Earnings declined 19.3%

Comparative Analysis Report

WallStSmart Research

Bull Case : DASH

The strongest argument for DASH centers on Revenue Growth, Market Cap, EPS Growth. Revenue growth of 37.7% demonstrates continued momentum.

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.

Bear Case : DASH

The primary concerns for DASH are PEG Ratio, Altman Z-Score, Profit Margin. A P/E of 72.3x leaves little room for execution misses.

Bear Case : MRK

The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.

Key Dynamics to Monitor

DASH profiles as a hypergrowth stock while MRK is a value play — different risk/reward profiles.

DASH carries more volatility with a beta of 1.90 — expect wider price swings.

DASH is growing revenue faster at 37.7% — sustainability is the question.

MRK generates stronger free cash flow (1.8B), providing more financial flexibility.

Bottom Line

DASH scores higher overall (59/100 vs 59/100) and 37.7% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

DoorDash, Inc. Class A Common Stock

CONSUMER CYCLICAL · INTERNET RETAIL · USA

DoorDash, Inc. operates a logistics platform that connects merchants, consumers, and merchants in the United States and internationally. The company is headquartered in San Francisco, California.

Visit Website →

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Want to dig deeper into these stocks?